Christina Voelkel-Johnson

Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL.

Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression.

An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells.

Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector.

In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer.

Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts.

Resistance to TRAIL is associated with defects in ceramide signaling that can be overcome by exogenous C6-ceramide without requiring down-regulation of cellular FLICE inhibitory protein.

Targeting the short form of cFLIP by RNA interference is sufficient to enhance TRAIL sensitivity in PC3 prostate carcinoma cells.

Illuminating TRAIL gene therapy.

Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2.

Transformation, translation and TRAIL: an unexpected intersection.

径组合疗法： 最近的事态发展和潜在的陷阱。

MDA-7/IL-24-induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK-dependent mechanism.

Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms.

The role of protein synthesis in cell cycling and cancer.

Oxidative stress and lymphocyte persistence: implications in immunotherapy.

Oxidative stress sensitizes bladder cancer cells to TRAIL mediated apoptosis by down-regulating anti-apoptotic proteins.

Inhibition of superoxide generation upon T-cell receptor engagement rescues Mart-1(27-35)-reactive T cells from activation-induced cell death.

Polymer-enhanced adenoviral transduction of CAR-negative bladder cancer cells.

17-allylamino-17-demethoxygeldanamycin and MEK1/2 inhibitors kill GI tumor cells via Ca2+-dependent suppression of GRP78/BiP and induction of ceramide and reactive oxygen species.

Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway.

Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells.

Adenoviral infectivity of exfoliated viable cells in urine: implications for the detection of bladder cancer.

T cells expanded in presence of IL-15 exhibit increased antioxidant capacity and innate effector molecules.

TRAIL-mediated signaling in prostate, bladder and renal cancer.

Histone deacetylase inhibitors restore cell surface expression of the coxsackie adenovirus receptor and enhance CMV promoter activity in castration-resistant prostate cancer cells.

Inner ear supporting cells protect hair cells by secreting HSP70.

Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma.